Clinical Trials Browser

Phase 1/2 × Withdrawn × Imatinib Mesylate × Clear all

NCT02812693 2018-04-05

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Phase 1/2 Withdrawn

Melanoma

NCT01188889 2015-05-15

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive